Search
for
Sort by
Research 151–180 of 1000+
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- A Comprehensive Review on Alopecia Areata and its Pathophysiology, Diagnosis, Treatment, and Psychosocial Impact
- A Comprehensive Review on Alopecia Areata and its Pathophysiology, Diagnosis, Treatment, and Psychosocial Impact
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Alopecia: A review of laser and light therapies
- Assessment of biotin supplementation among patients in an outpatient dermatology clinic
- Comment on “The post-finasteride syndrome: possible etiological mechanisms and symptoms”
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- What to Look for in Red Light Therapy: A Product Guide Backed by Science
- From Eye Care to Hair Growth: Bimatoprost
- International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
- Controversy: Synthetic hairs and their role in hair restoration?
- Biotin beware: Perils of biotin supplementation: Response to: “The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins”
- Response to Ranpariya et al.’s “Direct-to-consumer teledermatology platforms may have inherent conflicts of interest.”
- Alopecia Areata: Current and Emerging Therapies
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
- Novel agents for the treatment of alopecia
- Minoxidil in the treatment of androgenetic alopecia
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database